Antiarrhythmic medications are some of the most complex and high-risk drugs pharmacists encounter in clinical practice. In this episode, we break down the most important concepts pharmacists need to understand about antiarrhythmics, including the major drug classes and the clinical situations where these medications are commonly used.

A major focus of the discussion is medication safety. Many antiarrhythmics carry risks such as QT prolongation, proarrhythmia, and significant drug–drug interactions. Pharmacists play a critical role in identifying these risks, monitoring electrolytes and ECG changes, and recognizing situations where therapy adjustments are necessary. We also highlight why certain medications require inpatient initiation and careful monitoring.

The episode also covers practical clinical pearls, including the unique toxicity profile and interaction potential of amiodarone, how to think about rate control versus rhythm control strategies in atrial fibrillation, and the most common medication-related problems pharmacists should watch for. Whether practicing in ambulatory care, hospital, or long-term care settings, understanding antiarrhythmics can help pharmacists prevent serious complications and improve patient outcomes.

Be sure to check out our free Top 200 study guide – a 31 page PDF that is yours for FREE!

NAPLEX Study Materials

BCPS Study Materials

BCACP Study Materials

BCGP Study Materials

BCMTMS Study Materials

Meded101 Guide to Nursing Pharmacology (Amazon Highly Rated)

Guide to Drug Food Interactions (Amazon Best Seller)

Pharmacy Technician Study Guide by Meded101

P2Y12 inhibitors are a cornerstone of antiplatelet therapy in cardiovascular disease. These agents block the P2Y12 receptor on platelets, preventing ADP-mediated activation and reducing platelet aggregation. By inhibiting this amplification pathway, they help prevent arterial thrombosis in conditions such as acute coronary syndrome, percutaneous coronary intervention, stroke, and peripheral artery disease. The most commonly used oral agents include clopidogrel, prasugrel, and ticagrelor, each with important pharmacokinetic and clinical differences that influence agent selection.

From a pharmacist’s perspective, choosing the right P2Y12 inhibitor requires balancing ischemic benefit with bleeding risk. Clopidogrel requires CYP2C19 activation and is subject to drug interactions and genetic variability. Prasugrel provides more potent inhibition but carries a higher bleeding risk and is contraindicated in patients with prior stroke or TIA. Ticagrelor offers reversible inhibition but comes with unique considerations such as dyspnea and drug interactions via CYP3A4. Understanding these nuances allows pharmacists to optimize dual antiplatelet therapy and improve patient outcomes.

Be sure to check out our free Top 200 study guide – a 31 page PDF that is yours for FREE!

NAPLEX Study Materials

BCPS Study Materials

BCACP Study Materials

BCGP Study Materials

BCMTMS Study Materials

Meded101 Guide to Nursing Pharmacology (Amazon Highly Rated)

Guide to Drug Food Interactions (Amazon Best Seller)

Pharmacy Technician Study Guide by Meded101

In this episode, we explore several important non-statin cholesterol-lowering therapies, focusing on their mechanisms, clinical uses, and practical considerations for patient care.

We start with bile acid sequestrants, also known as resins, including cholestyramine, colestipol, and colesevelam. These medications lower LDL cholesterol by binding bile acids in the gut, prompting the liver to use more cholesterol to make new bile acids. They are effective for LDL reduction but may cause gastrointestinal side effects and have drug interaction considerations.

Next, we cover niacin (vitamin B3), which can lower LDL and triglycerides while raising HDL cholesterol. While niacin was historically widely used, its role has declined due to flushing, gastrointestinal symptoms, and potential liver toxicity.

Omega-3 fatty acids, including icosapent ethyl (EPA), primarily lower triglycerides and are used in patients with severe hypertriglyceridemia to reduce the risk of pancreatitis. Icosapent ethyl is a purified EPA formulation with evidence of cardiovascular benefit in select high-risk patients.

Finally, we discuss bempedoic acid, a newer oral agent that inhibits ATP-citrate lyase in the liver. Because it is activated only in the liver, bempedoic acid may be useful for patients with statin-associated muscle symptoms. Common adverse effects include elevated uric acid and mild increases in liver enzymes.

This episode highlights how these non-statin agents can be strategically used alone or in combination with other therapies to help patients reach their lipid goals and reduce cardiovascular risk.

Be sure to check out our free Top 200 study guide – a 31 page PDF that is yours for FREE!

NAPLEX Study Materials

BCPS Study Materials

BCACP Study Materials

BCGP Study Materials

BCMTMS Study Materials

Meded101 Guide to Nursing Pharmacology (Amazon Highly Rated)

Guide to Drug Food Interactions (Amazon Best Seller)

Pharmacy Technician Study Guide by Meded101